Mesenchymal Progenitor Cells and Their Orthopedic Applications: Forging a Path towards Clinical Trials by Shenaq, Deana S. et al.
SAGE-Hindawi Access to Research
Stem Cells International





DeanaS.Shenaq,1 FarbodRastegar,1 DjuroPetkovic,1 Bing-Qiang Zhang,1,2
Bai-ChengHe,1,2 LiangChen,1,2 Guo-WeiZuo,1,2 QingLuo,1,2,3 QiongShi,1,2 EricR.Wagner,1
EnyiHuang,1,4 Yanhong Gao,1,5 Jian-LiGao,1 Stephanie H. Kim,1 Ke Yang,1,6 Yang Bi,1,2,3
Yuxi Su,1,2,3 GaohuiZhu,1,2,3 JinyongLuo,1,2 XiaojiLuo,1,2 JiaqiangQin,1,2,3 RussellR.Reid,1
HueH.Luu,1 Rex C. Haydon,1 and Tong-Chuan He1,2,3
1Molecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, 5841 South Maryland Avenue,
MC3079, Chicago, IL 60637, USA
2Key Laboratory of Diagnostic Medicine Designated by Chinese Ministry of Education, The Aﬃliated Hospitals of
Chongqing Medical University, Chongqing 400016, China
3Stem Cell Biology and Therapy Laboratory, The Children’s Hospital of Chongqing Medical University, Chongqing 400014, China
4School of Bioengineering, Chongqing University, Chongqing 400030, China
5Department of Geriatrics, Xinhua Hospital of Shanghai Jiatong University, Shanghai 400092, China
6Department of Cell Biology, The Third Military Medical University, Chongqing 400042, China
Correspondence should be addressed to Tong-Chuan He, tche@surgery.bsd.uchicago.edu
Received 17 May 2010; Revised 7 July 2010; Accepted 28 September 2010
Academic Editor: Jin Sup Jung
Copyright © 2010 Deana S. Shenaq et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Mesenchymal progenitor cells (MPCs) are nonhematopoietic multipotent cells capable of diﬀerentiating into mesenchymal and
nonmesenchymal lineages. While they can be isolated from various tissues, MPCs isolated from the bone marrow are best
characterized. These cells represent a subset of bone marrow stromal cells (BMSCs) which, in addition to their diﬀerentiation
potential, are critical in supporting proliferation and diﬀerentiation of hematopoietic cells. They are of clinical interest because
they can be easily isolated from bone marrow aspirates and expanded in vitro with minimal donor site morbidity. The BMSCs
are also capable of altering disease pathophysiology by secreting modulating factors in a paracrine manner. Thus, engineering
such cells to maximize therapeutic potential has been the focus of cell/gene therapy to date. Here, we discuss the path towards
the development of clinical trials utilizing BMSCs for orthopaedic applications. Speciﬁcally, we will review the use of BMSCs
in repairing critical-sized defects, fracture nonunions, cartilage and tendon injuries, as well as in metabolic bone diseases and
osteonecrosis. A review of www.ClinicalTrials.gov of the United States National Institute of Health was performed, and ongoing
clinical trials will be discussed in addition to the sentinel preclinical studies that paved the way for human investigations.
1.Introduction:WhatAreStemCells?
The popularity of stem cells in the clinical arena has
signiﬁcantly increased, given the rapid improvement in our
understanding of their biology. Classically, stem cells are
deﬁned by their capacity to retain an undiﬀerentiated state
for a prolonged period while retaining the potential to
diﬀerentiate along one lineage (unipotent), multiple lineages
(multipotent), or into all three germ layers (pluripotent)
[1]. These cells can be broadly categorized into two major
classes:embryonicandadultstemcells.Embryonicstemcells
(ESCs), isolated from the inner cell mass of the blastocyst,
are pluripotent cells with the potential of diﬀerentiating into
tissues from all three germ layers [2, 3]. While ESCs have
signiﬁcant regeneration capacity, their clinical application
has been limited as a result of multiple factors including:
(1) a propensity to form teratomas, (2) ethical concerns
with isolation, (3) rejection by the host immune system2 Stem Cells International
after transplantation, and (4) the use of a feeder layer
to retain an undiﬀerentiated state in vitro [4–6]. Recently
discovered, another source of pluripotent stem cells are
induced pluripotent stem (iPS) cells, derived from somatic
cells treated with few deﬁned factors [7–11]. While iPS cell-
based therapy has the potential to revolutionize the ﬁeld of
regenerative medicine, many obstacles must be overcome
before their clinical application can be realized [12].
Furthermore, naturally occurring adult stem cells have
also been identiﬁed and categorized into either hematopoi-
etic stem cells (HSCs), a source of various hematopoietic
cell lineages, and nonhematopoietic stem cells, which can
give rise to cells of mesenchymal origin [13]. Many reports
have suggested that these nonhematopoietic stem cells,
also known as mesenchymal progenitor cells (MPCs), can
be isolated from various tissues including blood, adipose,
skin, mandible, trabecular bone, fetal blood, liver, lung,
and even the umbilical cord and placenta [14, 15]. Upon
harvest, these cells can be expanded in vitro with high
eﬃciency without sacriﬁcing diﬀerentiation capacity [16–
20]. While these multipotent progenitor cells share many
similar characteristics, they can be diﬀerentiated based on
their expression proﬁle and diﬀerentiation propensity along
various lineages [21]. Amongst the various sources, MPCs
isolated from the bone marrow, a subset of Bone Marrow
Stromal Cells (BMSCs) are considered to have the greatest
potential for multilineage diﬀerentiation and have been the
most characterized [22, 23].
BMSCs were initially described by Friedenstein and
colleagues more than 40 years ago as adherent cells, with
a ﬁbroblast-like appearance capable of diﬀerentiating into
osteoblasts, chondroblasts, adipocytes, and tenocytes [22,
24, 25]. Unlike ESCs, BMSCs provide the ﬂexibility of
autologous transplantation, circumventing ethical concerns
orimmunologicrejection[26].Thesecellsalsoplayasentinel
role in proliferation and diﬀerentiation of hematopoietic
cells [27]. Mankani et al. illustrated that the formation of
both hematopoiesis and mature bone organ is correlated
with the high local density of BMSCs [28]. Additionally,
BMSCs are considered to be immune privileged and have
the capacity for allogenic transplantation a property that
has been used in the clinical setting for the treatment of
various autoimmune diseases [29–31]. While many studies
have suggested that MPCs are immunoprivileged and do not
undergo rejection, others have cast doubt on this notion,
showing that in certain scenarios, MPCs induce immune
rejection [32]. More investigations should be conducted to
provide further insight into the speciﬁc interaction between
these progenitor cells and the host immune system.
Considerable eﬀort has been put forth to identify speciﬁc
surface markers that characterize MPCs, yet disagreement
within the literature has prevented the creation of deﬁnitive
standards. The minimal criteria identiﬁed by the Interna-
tional Society for Cellular Therapy for identifying BMSCs
requires the cells: (1) to be plastic adherent while maintained
in cell culture, (2) to express CD73, CD90, and CD 105
and lack expression of CD11b, CD14, CD19, CD34, CD45,
CD79-alpha, and HLA-DR, and (3) to diﬀerentiate into
osteoblasts, adipocytes, and chondroblasts in vitro [33].
Additional studies have also suggested that CD146 is consid-
ered an important marker of bone marrow progenitor cells
[34,35].Theseguidelinesweresetinplacetoenableauniﬁed
approach for comparison amongst diﬀerent studies.
Bone marrow is generally considered a milieu plentiful
for various cell types, collectively referred to as stromal
cells. Amongst these, the multipotent subset of BMSCs
comprises a small fraction (<0.01) [36], yet despite their
small numbers, the relative ease with which BMSCs can be
harvested has propelled their experimental use. Researchers
have pioneered the creation of stable animal models aimed
at mimicking human conditions to study the therapeutic
capacity of these bone marrow-derived cells [37]. Because of
their ubiquity, tolerance of expansion, paracrine capabilities,
and multipotency, the potential for clinical applications of
BMSCs in the orthopaedic realm is countless.
Inthispaper,wewillfocusonthedevelopmentofhuman
clinical trials utilizing BMSCs for orthopaedic applications.
The path towards the creation of such trials beginning
from sentinel animal investigations will be highlighted.
Speciﬁcally, the progenitor subset of BMSCs used in the
contextofcritical-sizeddefects,fracturenonunions,cartilage
andtendonrepair,metabolicbonedisease,andosteonecrosis
will be discussed. A review of www.ClinicalTrials.gov of the
United States National Institute of Health was performed to
underscore the status of ongoing clinical trials.
2. Modes of Use and Preparation
As previously mentioned, MPCs have been successfully
harvested from a variety of tissues; however, most clinical
trials utilize BMSCs for therapeutic applications. These cells
are harvested from the iliac crest and expanded ex vivo
in supplemental media. Cell expansion is currently a time-
consuming process, generally requiring 3–5 weeks to obtain
suﬃcient number for therapeutic application [38]. This
paper will touch upon the diﬀerent strategies for MPCs
preparation and use within the clinical arena, and therefore,
a prior overview of such approaches should be outlined. As
the most commonly used cell type for clinical application,
BMSCs can be administered through either autologous or
allogenic transplantation. In clinical trials, fresh autologous
BM and passaged BMSCs have been utilized for cellular
therapy[39].Freshlyharvestedaspiratescanfurtherundergo
centrifugation to concentrate BMSCs prior to percutaneous
or intravenous injection [40–42]. When expanded ex vivo,
various cell-speciﬁc characteristics are utilized to enrich pro-
genitor cells and separate them from other cells in the bone
marrow. One such characteristic that enables their selection
is BMSC preferential adherence to the plastic surface of
the culture dish [43, 44]. Immunoselection for previously
discussed MPC markers also enables further identiﬁcation
[45–47]. After expansion and selection, the harvested cells
can be utilized for various therapeutic applications.
Subsequent to ex vivo expansion, BMSCs can be cultured
in the presence of a scaﬀold-enabling colonization and cell
diﬀerentiation prior to material grafting at the aﬀected site
[48]. Preconditioning of the graft-scaﬀold composite can be
performed in vivo. For example, the composite can be ﬁrstStem Cells International 3
inserted into a heterotopic, richly vascularized area in order
to stimulate angiogenesis within the intended implant. After
adequategrowth,thenewlyvascularizedtissuecanbeexcised
and inserted into the desired site, thus increasing the chance
for cell survival [49]. Mankani and colleagues impreg-
nated BMSCs into a hydroxyapatitie/tricalcium phosphate
(HA/TCP) matrix and subsequently observed the generation
of mature bone with similar histologic and mechanical
properties to the bone formed with standard transplant
techniques in animal models [50]. The above-mentioned
modes of administration are only a few of the many methods
that various clinical trials have utilized to provide innovative
therapeutic strategies for many diverse clinical applications.
3.Critical-SizedBone Defects
Critical-sized defects are osseous defects beyond certain size
where complete healing will not occur during the lifetime of
the organism. Sixty years ago, the idea of autografting arose
as a solution for repairing large defects that would otherwise
not bridge in the normal environment. It was clear then
that tissue progenitors were necessary for eﬀective defect
repair. Classically, grafting involves the harvest of unaﬀected
pieces of tissue from remote sites and their implantation into
aﬀected areas. Yet, autograft use is limited by the lack of
suﬃcient donor tissue to ﬁll large defects and the morbidity
aﬄicted to the donor site. These clinical drawbacks have led
to the search for cells that could be induced to diﬀerentiate
and grow into the desired tissue type [51].
The concept of using cells to repair tissues is continually
evolving. The idea that MPCs possess the capacity for bone
regeneration in vitro and ectopically in vivo has been tested
and reaﬃrmed in various studies [52]. Promising results
spurned the development of animal models as building
blocks for the eventual clinical use of stem cells in humans.
These models can mimic (1) normal fracture healing, (2)
critical-sized segmental defects, and (3) non-critical-sized
defects, as in the case where healing is prevented by fracture
nonunions [51]. A variety of animal models including mice,
rats, dogs, sheep, and goats have been utilized to study the
role of MPCs in promoting repair in critical-sized defect.
These studies have also investigated critical size defects of
diﬀerent anatomical locations including: the femur, tibia,
metatarsal, mandible, and calvaria [53].
In a pilot study performed on a sheep model, Kon et al.
reported the use of autologous bone marrow stromal cells
in conjunction with hydroxyapatite ceramic (HAC) carriers
and demonstrated faster bone repair in the BMSC-treated
group as compared to HAC alone [54]. Potentially, this
combination could be used clinically for the treatment of
signiﬁcant long bone defects. In 2003, Arinzeh et al. further
expanded upon earlier trials and found that autologous and
allogeneic MPCs could repair critical-sized bone defects in
the canine model without immunosuppressive treatment
[55]. Kuznetsov and colleagues demonstrated that BMSCs
have the capacity to provide long-term bone augmentation
of the mandible [56]. In an earlier study, a similar group
concluded that BMSCs in conjunction with HA/TCP can
successfully close craniofacial bony defects in a mouse model
[57]. Biomechanically, the newly formed bone demonstrates
similar properties as the normal bone surrounding the defect
site [58]. Encouraging results from these animal studies
and others have paved the way for investigations involving
humans.
Quarto et al. provide one of the ﬁrst clinical reports
involving the repair of segmental diaphyseal defects in 4
patients using culture-enriched ex vivo expanded progenitor
cells [59].Autologousbonemarrowstromalcellswereplaced
on macroporous hydroxyapatite (HA) scaﬀolds, with their
size and shape dependent on the characteristic of the speciﬁc
bony defects. These grafts were stabilized via external ﬁxa-
tion. Integration at the bone-implant interface was observed
one month postoperatively and complete consolidation
was evident after 5–7 months. All patients recovered limb
functionwithnocomplicationsassociatedwiththeimplants.
At last followup (6 to 7 years postoperatively in patients 1
to 3), a good integration of the implants was maintained
without evidence of late fracture [60].
Ohgushi et al. have expounded upon earlier studies by
pioneering the production of bone matrix ex vivo. After
expanding marrow-derived MPCs, the investigators then
subcultured the osteoprogenitor cells to allow for the fab-
rication of osteoblasts/bone matrix onto various substrata.
The in vitro cultured regenerative bone was then delivered to
hospitals for surgical use. Care was taken to assure the risk
of bacterial/fungal contamination is minimized. Since 2002,
Ohgushi and colleagues have been utilizing these techniques
clinically for the treatment of chronic skeletal diseases (i.e.,
OA and benign bone tumors) [61].
The use of scaﬀolds or inert materials impregnated
with MPCs to generate three-dimensional implants is a
branch of tissue engineering which is rapidly growing. By
utilizing scaﬀolds, researchers attempt to create an in vivo
environment that favors the development of the desired
tissues for implantation. Seeding these composites with
the progenitor cells creates a potential for increased bony
regeneration because it enhances the repair process by
supplying progenitors that secrete factors. Perhaps one of
the greatest examples of this mode of tissue engineering for
bony regeneration is the case report by Vacanti et al., where
the authors replaced the avulsed phalanx of a 36-year-old
manwithperiostealprogenitorcellsharvestedfromthedistal
radius seeded onto a natural coral (porous HA) scaﬀold.
This procedure resulted in the functional restoration of a
biomechanically sound thumb of normal length, without the
comorbidity associated with harvesting bone grafts [62].
Promising preclinical studies and case reports have pro-
vided support for the therapeutic role of culture-expanded
osteoprogenitor cells and their application in conjunction
with diﬀerent scaﬀolds for healing of long bone defects
in clinical trials. Hoping to take advantage of this tissue-
engineering approach, Emory University gained approval
in March 2009 to conduct a Phase II/III randomized,
single-blinded control trial with 50 participants utilizing
the allograft substance Trinity in the repair of bony deﬁcits
in patients with benign disease (NCT00851162). Trinity is
currently FDA approved for use in traumatic bony defects
including the spine. MPCs, along with an allograft carrier,4 Stem Cells International
can incorporate and induce bone formation. The MPCs are
preimmunodepletedand,therefore,donotstimulatelocalT-
cellproliferationbutinsteadareactivatedtoactasosteoblasts
promoting bone formation. As this study is ongoing, no
results have been made available.
ThetherapeuticpotentialofMPCshasalsobeenreported
in the treatment of critical-sized defects of the craniofacial
skeleton. Lendeckel et al. reported improved healing in a 7-
year-old girl suﬀering from widespread traumatic calvarial
defects, who was treated with autologous adipose-derived
MPCs [63]. While CT-scans demonstrated new bone for-
mation, whether the regenerate was a direct outcome of
donor cell diﬀerentiation or rather a paracrine eﬀect induced
by local cells, remains to be elucidated. In another case
report, tissue-engineered osteogenic material was injected
into a patient undergoing distraction osteogenesis utilizing
a ﬁbular ﬂap for mandible reconstruction. The material
was comprised of autologous, culture-expanded MPCs that
were induced towards osteogenesis via platelet-rich plasma
(PRP) activated by thrombin and calcium chloride. Full
consolidation of the regenerate was observed after 3 months.
Postinjection,theregeneratedridgebecamethicker,andthus
aided in bridging a gap between the native mandible and
distracted ﬁbula [64].
In case reports, other groups have also reported the
eﬃcacy of BMSC transplantation in combination with
PRP for bone regeneration during distraction osteogenesis
[65]. Ueda et al. used this mode of tissue engineering by
combining PRP and beta-tricalcium phosphate as grafting
materials for maxillary sinus ﬂoor augmentation with simul-
taneous implant placement in 6 patients. A mean increase in
mineralized tissue height of 7.3 ± 4.6mm was evident when
comparing the pre- and postsurgical radiographs. Thus, in
thesecases,injectabletissue-engineeredboneprovidedstable
and predictable results in terms of implant success [66].
4.Non/DelayedUnions
During normal fracture healing, undiﬀerentiated MPCs are
recruitedtoinjurysitesandundertheinﬂuenceofregulatory
cytokines (e.g., BMPs), and they proliferate and diﬀerentiate
into chondrocytes and osteoblasts to repair the defect. While
many fractures under appropriate conditions heal properly,
somefailtohealduetoavariety ofcausesassociatedwiththe
host, the surgical technique, inadequacy of the vasculature,
and infection amongst other causes. At the cellular level,
non-union is deﬁned as the cessation of both periosteal
and endosteal healing without bridging [67]. Nonunions
complicate approximately 10%–20% of 6 million fractures
occurring each year in the United States [68]w h e r e a s
the incidence varies by fracture location. While it remains
a common clinical concern, management of nonunions
remains a challenge.
In 1978, Salama and Weissman described the ﬁrst
attempt to utilize the osteogenic potential of BMSCs to
manage delayed fracture healing in the clinical arena [69].
The authors combined bone xenografts with autologous
bonemarrowaspiratesforgraftingin28patientsforavariety
of clinical indications. The treatment of tibial nonunions
with autologous marrow injections was expanded further by
Connolly et al. who combined this method with either cast
immobilization or intramedullary nailing in 20 successful
cases over a ﬁve-year period [70]. In a followup series of
100 patients, Connolly also employed this technique in the
treatment of delayed unions and nonunions of fractures,
arthrodeses, and bone defects [71]. Since the original report
by Salama et al., numerous researchers have begun utilizing
bone marrow aspirates as adjuncts in the treatment of non-
or delayed unions with promising results [72].
Hernigou et al. further emphasized the potential role
of progenitor cells in bony healing in a study of 60 tibial
atrophic nonunions. Using percutaneous injection of a
concentrated buﬀy coat obtained from the centrifugation of
autologous iliac crest bone marrow aspirates, the authors
noted a positive correlation between the volume of the min-
eralized callus and the number and concentration of progen-
itor cells in the aspirate. Analysis of the buﬀy coat revealed
the presence of progenitor cells and other mononuclear cells,
most likely providing osteogenic and angiogenic inﬂuences.
In the 7 patients where union was not accomplished, the
concentration of stem cells injected appeared signiﬁcantly
lower than in patients with osseous union (P = .001 and
P<. 01). Perhaps a limitation in this study is the lack of a
controlgroupwithplacebotreatment[41];however,thedata
demonstrates that successful treatment of nonunion with
percutaneous bone marrow grafting is dependent upon the
number and concentration of progenitor cells.
In 2005, Goel et al. embarked on a prospective clinical
study to evaluate the eﬃcacy of percutaneous bone marrow
grafting in 20 patients with established tibial nonunions
with minimal deformity, while they waited for open surgical
procedures [73]. Three to ﬁve milliliters of marrow was
aspirated from the iliac crest and injected immediately into
and about the site of non-union. Subsequent aspirations
were performed 1cm posterior to the previous site until
a maximum of 15ml of marrow was injected. Clinically
and radiologically, bony union was documented in 15
out of 20 patients (75%), with an average time to union
following the ﬁrst injection of 14 weeks. Four patients (20%)
showed no evidence of union and were considered a failure.
There were no cases of infection following the injections,
and no complications at the donor site. Based on these
promising results, the authors concluded that percutaneous
bone marrow grafting can be considered a safe, simple, and
reliable technique for managing non-unions. This minimally
invasive method of treating tibial non-unions without defor-
mity can potentially allow the avoidance of major surgical
reconstruction in qualiﬁed patient populations.
Maneerit et al. conducted one of the ﬁrst prospective
randomized clinical trials examining the use of bone marrow
in the treatment of non- or delayed unions over a 2.5-year
period [74]. They compared outcomes between percuta-
neous bone grafting and open bone grafting of tibial shaft
fractures or high-energy tibial fractures which required early
prophylactic bone grafts. Subjects were randomized to either
percutaneous bone graft (n = 15) or open bone graft (n =
15). Percutaneous bone graft technique was associated with
signiﬁcantly less blood loss (P<. 01) and shorter operativeStem Cells International 5
time (P<. 01) although one patient in the percutaneous
group had posterior tibial nerve palsy postoperatively with
complete recovery after 6 weeks. No diﬀerences in rate of
union, healing time of the successful cases, postoperative
pain and hospital stay were observed, indicating that the
percutaneous technique has eﬀective results similar to the
open technique in promoting union of tibial fractures.
Entering the realm of clinical trials marks an important
milestone on the pathway to approval of MPC therapy for
bony non-unions. In October 2003, Aastrom Biosciences
enrolled 36 patients who had failed previous surgical inter-
vention with long-bone atrophic non-unions from type IIIA
or IIIb fractures with fracture gaps of <6cm in a mul-
ticenter, nonrandomized, open-label uncontrolled, single-
group phase I/II clinical trial (NCT 00424567) [52]. Subjects
were treated with open reduction and internal ﬁxation
and an allograft bone matrix graft extender plus BMSCs
expanded from autologous iliac crest aspirates. In April
2009, the Hadassah Medical Organization in Israel began a
randomized, open-label, single-group Phase I/II clinical trial
for the treatment of distal tibial fractures (NCT00250302).
Twenty-fourpatients with distal tibial fractureswithoutjoint
involvement will undergo autologous implantation of MPCs
loaded onto carriers at fracture sites to determine the safety
and eﬃcacy of this mode of treatment.
5. CartilageRepair
Chondral defects secondary to accidental trauma, necrosis
of subchondral bone tissue, or arthritis have become some
of the more common conditions today [79]. Approximately
15% of the world’s population reportedly suﬀers from
joint diseases. However, despite ongoing research, repair
and regeneration of cartilage defects remains a challenge in
orthopaedic surgery. Human cartilage is characteristically
avascular and depends on diﬀusion from cyclical loading
during joint movement for nutrient acquisition [80]. Given
their unique microenvironment, chondrocytes have adapted
to a low basic metabolic rate and have limited potential to
increasetheirmetabolicactivitytoallowfortissuerepair.Asa
result, articular cartilage is considered a tissue with minimal
intrinsic repair capacity in vivo.
Currently, many of the treatment modalities including
drug therapy, arthroscopy, and prosthetic joint replacement
provide symptomatic relief but do not directly address the
underlying pathophysiology [81]. Other treatment modali-
ties for cartilage repair, which aim to address the underlying
molecular cause, range from bone marrow stimulation,
mosaic plasticity, and autologous chondrocyte implantation
(ACI). ACI is a method ﬁrst reported by Brittberg et al.
in 1994 [82]. In this technique, chondrocytes are isolated
from the cartilage of nonweight bearing sites and expanded
ex vivo. These expanded cells are subsequently injected into
the defect sites and covered with an autologous periosteal
ﬂap to ensure cell adherence. Initial clinical trials of ACI
showed promise [83]; however, this treatment requires the
extraction of chondrocytes directly from the patient and
thus causes trauma to healthy articular cartilage. Other
disadvantages of ACI include: leakage of transplanted cells,
periosteal hypertrophy, loss of the chondrocyte phenotype in
the expanded cells in monolayer culture, lack of applicability
to large lesions, and decreased eﬃcacy in patients over 40
years due to low cellular activation levels. Additionally, the
newly regenerated cartilage often consists of ﬁbrocartilage,
rather than the desired hyaline cartilage within the joint
space [84].
Researchers tried to address these initial pitfalls with
the development of a second generation ACI procedure.
This method employs various biomaterials such as collagen
type I gel, hyaluronin-based scaﬀolds, and collagen type
I/III membranes to recreate a 3D environment ideal for
expression of chondrogenic phenotypes and to secure cells
within the defect site in lieu of a periosteal ﬂap [85–87].
However, prospective clinical studies comparing ﬁrst and
second generation ACI failed to show signiﬁcant diﬀerence
in short-term clinical outcomes [88].
Although current technologies may improve morbidity
associated with local cartilage defects, they still fall short in
thetreatmentofsystemicarthriticdisease.BMSCtherapyfor
cartilage disorders is principally sound since progenitor cells
are typically harvested from the iliac crest, circumventing the
need to damage healthy articular cartilage. Furthermore, the
number of successfully cultured cells is larger due to their
excellent proliferation capacity enabling abundant supply.
The chondrogenic potential of MPCs was ﬁrst reported
by Ashton et al. in 1980 [89], and since then, many
researchers have focused on delineating the mechanism
underlying chondrogenic diﬀerentiation [90–92]. Currently,
only one prospective clinical trial of BMSC transplantation
for repair of cartilage defects has been published. Wakitani
et al. recruited 24 patients with knee osteoarthritis who
underwent a high tibial osteotomy to examine the eﬀects
of a cellular versus noncellular impregnated scaﬀold on
cartilage defects in the medial femoral condyle [76]. For the
cellular arm, bone marrow-derived MPCs were suspended in
a type I collagen gel and transplanted with an autologous
periosteal ﬂap into the defect site. The control group also
received a periosteal ﬂap but with a cell-free scaﬀold. No
clinically signiﬁcant improvement was observed in the cell-
treated group versus controls, but the arthroscopic and
histological scores were higher in the BMSC transplanted
subjects. Furthermore, in a later study, the same group
investigated the eﬃcacy of autologous BMSCs for repair of
cartilage defects and demonstrated clinical and histological
improvement in the treated patients [75].
Case reports from the same research group also docu-
ment improvement in clinical symptoms following BMSC
transplantation [93], but comparative clinical trials with
other surgical methods must be performed to assess the
utility of this type of tissue engineering in humans. Black
et al. published the ﬁrst randomized, double-blind, multi-
center control trial examining the eﬀectiveness of stem cell
therapy in dogs [94]. They explored the eﬀects of adipose-
derived stem cells (ASCs) on lameness in dogs with chronic
osteoarthritis of the femoral joint. Dogs treated with ASCs
showed signiﬁcantly improved scores for lameness pain, and
range of motion compared with control dogs. While these
studies show promising results, it is important to identify6 Stem Cells International
the paracrine potential of ASCs and their eﬀect on clinical
outcomes.
Numerous clinical trials are ongoing to examine the
utility of MPC therapy in the treatment of cartilage defects.
Cairo University School of Medicine has undertaken a Phase
II/IIIclinicaltrialwhichbeganinDecember2006toexamine
whether implanting autologous, culture-expanded MPCs,
obtained from patients with early OA, cartilage defects, or
osteochondral joint disease, is eﬀective in treatment of such
conditions. Twenty-ﬁve subjects will undergo bone marrow
aspiration from the iliac crest with implantation of the ex
vivo expanded MPCs into defect sites via open surgery or
arthroscopy (NCT00891501). Starting in August 2008, The
Royan Institute of Tehran University of Medical Sciences
enrolled 6 patients in a Phase I study aimed at investigating
the eﬃcacy and safety of autologous transplantation of
BMSCs mixed with a collagen I scaﬀold in cartilage defects
and osteoarthritis of the knee (NCT00850187). Ullevaal
University Hospital in Oslo, Norway began a Phase I clinical
trial in April 2009, enrolling 50 patients, to compare the
treatment eﬃcacy of autologous MPCs versus chondrocytes
implanted in a commercially available scaﬀold in patients
with cartilage defects (NCT00885729).
In an in vivo study of osteoarthritis in a caprine model,
Murphy et al. demonstrated that intra-articular injection of
BMPCs at sites of meniscal injury resulted in engraftment
of those cells and regeneration of meniscal tissue to produce
a chondroprotective eﬀect [95]. Based on results from this
in vivo trial, Osiris Therapeutics completed a Phase I/II
placebo-controlled, RCT in February 2008 of 60 patients
to examine the safety and eﬃcacy of hMPCs suspended in
a solution of hyaluronic acid (Chondrogen) for the repair
of meniscal tissue following meniscectomy. In Chondrogen
treated subjects, surgically removed meniscal tissue was
regenerated, cartilage surface was protected, and joint dam-
age was decreased in comparison to control subjects. These
beneﬁts persisted for at least one year. As a followup study, in
June 2008, Osiris Therapeutics began a second randomized,
placebo-controlled Phase I/II clinical trial to examine the
long-termsafetyofhighandlow-doseBMSCs(Chondrogen)
in the repair of meniscal tissue following meniscectomy
(NCT00702741).Inthis3-yearfollowupstudy,thetreatment
group will receive a single intra-articular injection of 50 mil-
lion donor-derived hMPCs (low dose) or 150 million donor-
derived hMPCs (high dose) in suspension with commercial
sodium hyaluronan and will be compared to control patients
receivinganinjectionofavehicle(dilutedhyaluronan)alone.
Although bone marrow provides a good source of stem
cells, interest in MPCs derived from the umbilical cord blood
(UCB) has recently emerged. Some studies have suggested
that the prevalence of MPCs is much higher in preterm UCB
as compared to samples obtained from term fetuses [96].
VariousstudieshavesuggestedthatMPCsisolatedfromUCB
have the highest level of activity among all adult stem cells
[97]. Using umbilical cord blood for the harvesting pro-
genitor cells also forgoes the ethical implications associated
with harvesting embryonic stem cells. With this in mind, in
February2009,MedipostCoLtd.beganarandomized,open-
label, multicenter and Phase 3 clinical trial of 104 patients
to compare the eﬃcacy and safety of allogeneic-unrelated
umbilical cord blood-derived MPC product (Cartistem) to
that of a microfracture treatment in patients with articular
cartilage defects or injuries (NCT01041001). MPCs were
isolated from umbilical cord blood, cultured with semi solid
polymer, and surgically administered into lesion sites in
order to stimulate the regeneration of defective cartilage
tissue.
6. Osteonecrosis (ON)
The treatment of osteonecrosis of bone is another arena
where cell-based therapies can play a pivotal role. These
injected bone marrow cells most likely secrete cytokines
that promote angiogenesis and subsequent osteogenesis
[98].
Hernigou proposed the use of bone marrow trans-
plantation for treatment of osteonecrosis of the humeral
head in 1997 in the case of a 13-year-old patient with
sickle cell disease [99]. The donor was an HLA-identical
sibling who was heterozygous for sickle cell anemia. Marrow
transplantation by intravenous infusion was performed after
administration of chemotherapy and total lymphoid irradi-
ation. Three months post transplantation, pain and range of
motionwassigniﬁcantlyimproved,andradiographsrevealed
rapid reconstruction of the left proximal humerus epiphysis,
with a tendency toward normalization of the marrow signal
apparent via T1-weighted MR imaging. Thereafter, many
clinical studies followed to examine the role of bone marrow
aspiratesinthetreatmentofONinvariousskeletallocations,
demonstrating promising results for the early stages of
disease (Table 1)[ 100].
In January 2009, Fuzhou General Hospital in China
approved a study to enroll 30 patients in a clinical trial to
examine the safety of expanded autologous MPCs infused
into the femoral artery of patients with osteonecrosis of
the femoral head (NCT00813267). Patients will undergo
MPC infusions at the start of the study on day 0 followed
by subsequent injections at 6-month intervals. They will
be evaluated using digital subtraction angiography, X-ray
examination, and CT and MRI scanning.
7. Osteogenesis Imperfecta(OI)
OI is a heterogeneous group of inherited disorders char-
a c t e r i z e db ya b n o r m a lp r o d u c t i o no ft y p eIc o l l a g e nb y
osteoblasts leading to osteopenia, multiple fractures, severe
bony deformities and short stature [101–103]. It has variable
clinical phenotypes, ranging from subclinical presentation
and normal life expectancy to osteopenia or death [104].
Currently, pharmacological management is the treatment
of choice. Many studies have demonstrated the utility of
bisphosphonate therapy in OI for increasing bone density,
strength, and reducing the number of fractures [105];
however, these eﬀects must be conﬁrmed by double blind,
randomized control trials. Many researchers also worry
about the potential adverse eﬀects of bisphosphonates on the
child skeleton, and therefore, raised concern regarding long-
term outcomes [106].Stem Cells International 7
Table 1: Clinical studies of bone marrow aspirates in osteonecrosis.
Authors Year Study Description Main ﬁndings
Hernigou
et al. 1997 Case report 13-year-old with SSA and ON of humeral head treated
with allogenic bone marrow transplantaion
Improvement in pain and motion range; X-Rays
at 3 months showed signiﬁcant regeneration of







189 hips in 116 patients were treated with core
decompression and with ABM harvested from anterior
iliac crests; the aspirated marrow was reduced in
volume by concentration and injected into the femoral
head after core decompression with a small trocar;
followup of 5–10 years
In 145 of the stage I/II patients, hip replacement
was required in 9; total hip replacement was
necessary in 25 of 44 hips operated on at stage
III/IV patients with greater number of OPGr cells
transplanted had better outcomes
Gangi
et al. 2002 Prospective
control
Treatment of 18 hips with stage 1 or 2 (ARCO) femoral
head ON with either core decompression alone or in
combination with ABM injection
Signiﬁcant reduction in pain and joint symptoms
at 2 years; 5 of 8 hips in control group
deteriorated to stage 3 compared to 1 hip in
treatment arm
Yan et al. 2006 Prospective
noncontrol
Treatment of 44 hips with stage 3 or 4 (ARCO) femoral
head ON with ABM injection
Mean Harris hip score improved from 58 (46–89)
to 86 (70–94) at 2 years; no complications
Kawate
et al. 2006 Case reports
Treatment of 3 patients with steroid-induced ON of
femoral head (ARCO Stages 4A–4C) by transplantation
of autologous MSCs cultured with beta-tricaclium
phosphate ceramics and free vascularized ﬁbulas
Early bone regeneration observed but
radiographic progression was seen in 2 of 3
patients at mean followup of 34 months
Lee et al. 2009 Case reports
Three patients with bilateral, large lesions (0.32 of
femoral width) of ON of the femoral condyles treated
by decompression, debridement, and ABM grafting
using the Cellect DBM System to increase the number
of OPGr cells from the aspirate
Cellect provided graft matrix enriched with a
3-fold to 4-fold increase in OPGr cells; no
complications at 2 years with all 3 patients
achieving near-normal function and activity levels
ABM: autologous bone marrow; ARCOL: association research circulation osseous; OPGr: osteoprogenitor; SSA: sickle cell anemia.
Table 2: Examples of the therapeutic applications of MPCs in humans.
Indications Source Mode of administration Outcome
Fracture
nonunion
Autologous BM 100% hydroxyapatite macroporous
ceramic scaﬀolds with MPCs
X-ray & CT evidence of bone formation:
recovered limb function [60]
Autologous BM Subcutaneous
Correlation between volume of mineralized
callus and concentration of progenitor cells in
the aspirate [40]
Cartilage defect Autologous BM Direct site transplantation Improved clinical symptom and coverage of
defect [75]
Autologous BM Cells embedded in collagen gel
transplanted at site of cartilage defect




Fetal MSC Intrauterine transplantation Osteoblastic diﬀerentiation and reduced
fracture [77]
Gene-marked
Allogenic MPCs IV infusion×2
5 out of 6 patients demonstrated bone
engraftment and increase in bone velocity
[78]
Critical size







Local administration of cells with
ﬁbrin glue
CT scans showed new bone formation and
near complete calvarial continuity 3 months
postoperatively [63]
MPC: mesenchymal progenitor cell, BM: bon marrow, IV: intravenous.
AnalternativetreatmentisthetransplantationofBMSCs,
which in principle should alleviate or resolve a genetic
disorder of bone. In fact, preclinical experiments carried
out in animal models revealed that transplanted marrow
stromal cells can migrate and incorporate into bone of
recipient animals [107]. Horwitz et al. have been utilizing
allogeneic bone marrow transplantation for the treatment of
severe OI in children since 1999 [108]. In their latest case
report, the authors described the use of gene-marked, donor
marrow-derived mesenchymal cells to treat 6 children who
underwent standard bone marrow transplantation for severe
OI. Each child received two infusions of the allogeneic cells.8 Stem Cells International
One patient developed an urticarial rash immediately fol-
lowing the second infusion, but otherwise, no clinically
signiﬁcant toxicity was reported [78].
Taking the concept of bone marrow transplantation for
OI one step further, Le Blanc and colleagues performed an
intrauterine transplantation of a female fetus diagnosed with
severe OI at 32 weeks of gestation with MPCs isolated from
a HLA-mismatched male fetus [77]. At 9 months of age,
bone histology showed regularly arranged and conﬁgured
bone trabeculae. Patient lymphocyte proliferation against
donor MPC was not observed in coculture experiments
performed in vitro after MPC injection. During the ﬁrst 2
years of life, three fractures were noted, and at 2 years of
corrected age, psychomotor development was normal, and
growth followed the same channel. Given these ﬁndings, the
authors concluded that allogeneic fetal MPCs can engraft
and diﬀerentiate into bone in a human fetus even when the
recipient is immunocompetent and HLA-incompatible.
Encouraged by previous clinical experiences, Horwitz
et al. have begun a Phase I, nonrandomized control trial
of 12 patients with Type II or III OI in order to evaluate
the safety and eﬀectiveness of repeated BMSC infusions
(NCT01061099). Group A will consist of patients who
have previously undergone bone marrow transplant
whereas those in Cohort B lack a history of bone marrow
transplantation. All participants will receive BMSC infusions
approximately every 4 months to complete a total of 6
infusions over a 20-month period and will be followed for 4
months after their last infusion.
Drexel and Wayne State University underwent a Phase
I pilot study from July 1999 to January 2008 of 8 patients
with osteodysplasia who had undergone a previous bone
marrow transplantation (NCT00186914). They were infused
twice with ex vivo expanded, allergenic, gene marked donor
BMSCs. The ﬁrst dose was given at least 6 months post
transplant and the second at 14 to 21 days after. Since
the stromal cells were obtained from the original stem cell
donor, no conditioning was required. Study results are still
pending.
8. Tendon Repair
Currently, experimental animal models are in progress to
establish convincing evidence for enhanced tendon repair
with progenitor cell therapy, but advancements in the ﬁeld
have not yet reached the level of clinical trials. Investigations
to date have demonstrated the utility of Type I collagen com-
bined with autologous, expanded BMSCs for improving the
biomechanical properties of injured rabbit tendons although
diﬀerences in microstructure have yet to be seen [109].
Using an equine model, Crovace et al. injected and
compared cultured bone marrow mesenchymal stem cells
(cBMSCs) and bone marrow mononucleated cells (BMM-
NCs) versus placebo for treatment of collagenase-induced
tendonitis in the horse. At 21 weeks, histological analysis
and immunohistochemical stains with H&E and Herovici
for collagen type I and III revealed mature type I collagen
with normal architecture in tendons treated with cBMSC
and BMMNC, while random collagen type III organization
was observed in the placebo group. These results suggest that
cBMSC and BMMNCs have the potential to promote tendon
regeneration in an equine collagenase-induced tendonitis
model [110]. Authors have also used BMSCs seeded onto
various scaﬀolds and found that introducing autogenous
mesenchymal progenitor cells onto composites signiﬁcantly
improved tendon repair compared to the use of a composites
alone in the rabbit model [111].
One potential pitfall of BMSC therapy for tendon repair
is the potential for ectopic bone production at the site
of injury. Harris et al. observed this phenomenon in 28%
of BMSC-treated rabbit tendons and concluded that better
controlofthediﬀerentiationpathwaywithadditionalinvitro
testing is necessary prior to embarking on clinical trials with
MPC therapy in tendon repair [112].
9.The FutureofStemCells
Much attention has been engendered for combining the
principles of stem cell therapy with those of gene therapy
to engineer cells that can complement cellular function in
genetic disorders, as discussed previously. Gene therapy can
beexecutedexvivowiththegeneofinterestintroducedtothe
progenitor cells followed by its readministration back into
the patient, thereby replacing the missing factor in the host.
To date, these approaches have only been studied in animals
but with great success.
Prior to embarking on clinical trials, the vectors used to
deliver genes of interest must be optimized. Recombinant
formsofbonemorphogenicproteins(rhBMPs),forexample,
have been used in animal models to promote and hasten
osteogenesis [113]. Based partly on this in vivo work, the
US Food and Drug Administration approved the use of
the rhBMP-2 and rhBMP-7 in spinal fusions and tibial
non-unions,respectively.Althoughpromisingandseemingly
eﬀective, rhBMPs have multiple disadvantages, namely, the
requirement of supraphysiologic concentrations and low
biological activity due to high rates of clearance from the
defect sites [114]. In addition, high costs and diﬃculty of
production are potential factors limiting the use of rhBMPs
in clinical practice.
An alternative mode of applying BMPs is through their
expression using adenoviral vectors. This form of gene
therapy is able to deliver recombinant BMP DNA to cells
at the defect sites [115]. Treated cells can then synthesize
and secrete their own endogenous BMPs and supply the
extracellular environment with a continuous concentration
of osteoinductive signaling factors without the need of
reapplication [114] .T h e s ea d e n o vi ra lv e ct o r sp r o vi d eas h o rt
but high level expression of the gene of interest, which is
suﬃcient to promote osteoblastic diﬀerentiation and subse-
quent bone formation [116]. Baltzer et al. used adenoviruses
expressing BMP-2 (AdBMP-2) to induce healing of critical-
sizedbonedefectsinratfemurs[117],andotherinvestigators
havefollowedsuit[118].Ourlaboratoryfocusesinparticular
on the role of adBMP-9 in osteogenic diﬀerentiation of
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However, in vivo transfer of genes utilizing viral vectors
provokes the possibility of immune reaction, which will
prevent treatment eﬃcacy. And thus, because of the strong
potential for adverse reaction, utilizing adenovirus in human
trials remains distant. Current strategies underway involve
ex vivo genetic modiﬁcation of autologous BMSCs via
adenoviral vectors followed by their reimplantation in vivo.
This approach avoids the transfer of viral particles or DNA
directly into the patient and would most likely forgo the
immune response associated with direct viral administration
[120]. To date, however, ex vivo adenoviral gene therapy has
been utilized only in animal models.
Concern surrounding the use of viral vectors as vehicles
for gene delivery has prompted the utilization of other
methods to genetically modify MPCs. Nucleofection is a
modiﬁed electroporation technique that has been used
by many diﬀerent groups for genetic modiﬁcation of
BMSCs [121–123]. FuGENE 6, a cationic polymer-based
commercially available transfection reagent, has also been
successfully used to genetically engineer MPCs [124–126]. In
addition, liposome-mediated transfection of MPCs has also
been reported [127]. While these novel nonviral methods
of transfecting cells are promising, signiﬁcant research is
necessary to delineate their eﬀectiveness.
Genetic engineering of BMSCs is ideal, as it eliminates
the requirement of large amounts of cells for implantation
and culture expansion. Although the morbidity associated
with bone marrow aspiration for the accrual of MPCs is
less than previous methods of defect repair that utilized
autologous bone grafting, researchers remain interested in
developing more minimally invasive means of harvesting
progenitor cells. One such modality which has gained
popularity isutilizingadiposetissueasasourceofprogenitor
cells. Given the ease of harvest and the availability of adipose
tissue, many researchers are currently interested in under-
standing the mechanisms underlying the diﬀerentiation
capacity of adipose-derived progenitor cells (APCs) [128].
While adipose-derived MPCs show signiﬁcant promise as
an important source of MPCs, further research into their
characteristicsasprogenitorcellsisnecessarytoharnesstheir
utility in the clinical setting.
10. Conclusion
The therapeutic capacity and safety of BMSCs have been
documented in numerous animal experiments in vivo.
Currently, 107 clinical trials utilizing exogenous BMSCs
to treat a wide range of conditions are registered with
ClinicalTrials.gov (Tables 2 and 3). Although many are
also underway to examine the role BMSCs in orthopaedic
associated tissue regeneration, limited evidence is currently
available to support routine use. Results from large-scale
multicenter clinical trials must be completed and analyzed
prior to reaching the ﬁnal destination of FDA approval for
utilizing cell-based therapy to manage orthopaedic patients
in the clinic. Given the abundance of ongoing investigations,
however, we can expect a profuse amount of new clinical
data in the near future. Science has progressed inﬁnitely
since Friedenstein’s pioneering studies in the 1960s, and with
the continuation of human trials, we move one step closer
towards applying BMSC therapy as a novel paradigm.
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